Sector Update: Health Care Stocks Rise in Monday's Premarket Hours
Express News | Zymeworks Inc - FDA Clears Ind Application for ZW191
Express News | Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks (NASDAQ:ZYME) Shareholders Are up 9.5% This Past Week, but Still in the Red Over the Last Three Years
Zymeworks to Unveil Q2 2024 Results and Drug Progress
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
H.C. Wainwright Maintains Zymeworks(ZYME.US) With Hold Rating, Maintains Target Price $10
Zymeworks Analyst Ratings
Zymeworks ZW171 IND for Mesothelin-expressing Cancers Cleared by FDA
Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy
Market-Moving News for June 17th
Express News | Zymeworks Shares Are Trading Higher After the FDA Cleared the Company's Investigational New Drug Application for Zw171 for Mesothelin-expressing Cancers, With the Company Expecting to Initiate Clinical Development During 2024
Express News | Zymeworks Shares up 4.1% Premarket After FDA Clears Co's Application to Start Trials in Humans for Cancer Drug
Express News | FDA Clears Zymeworks' Investigational New Drug Application For Zw171 For Mesothelin-expressing Cancers, The Company Expects To Initiate Clinical Development Of Zw171 During 2024
Express News | Zymeworks: To File Applications Seeking Regulatory Permission to Commence Clinical Studies for ZW171 in Other Non-US Jurisdictions in H2 2024
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a Novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Express News | Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a Novel 2+1 T-Cell Targeting Bispecific Antibody for Mesothelin-Expressing Cancers
Zymeworks (NASDAQ:ZYME) Investors Are Sitting on a Loss of 75% If They Invested Three Years Ago
Subdued Growth No Barrier To Zymeworks Inc.'s (NASDAQ:ZYME) Price
Form 144 | Zymeworks(ZYME.US) Insider Proposes to Sell 774.06K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 11, $Zymeworks(ZYME.US)$ Insider Christopher Astle intends to sell 86,294 shares of its common stock on Jun 11, with a total market value of approximately $774.06K. Sour